---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-050376"
form_type: "8-K"
ticker: "OVID"
cik: "0001636651"
company_name: "Ovid Therapeutics Inc."
filed_at: "2021-10-07T23:59:59+00:00"
generated_at: "2026-06-28T22:15:07.473212+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Ovid Therapeutics appoints Dr. Kevin Fitzgerald as director, grants stock options

## Summary
- Appointed Dr. Kevin Fitzgerald, Ph.D. to Board as Class II director effective Oct 6, 2021.
- Initial option for 30,000 shares at $3.44 exercise price, vesting monthly over 3 years.
- Annual cash compensation of $40,000 prorated; eligible for 15,000-share annual option grant.
- No arrangements or understandings with any other person regarding appointment; no family relationships.
- Standard indemnity agreement entered; compensation per Non-Employee Director Compensation Policy.

## SEC filing metadata
- accession: 0001564590-21-050376
- form_type: 8-K
- ticker: OVID
- cik: 0001636651
- company_name: Ovid Therapeutics Inc.
- filed_at: 2021-10-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636651/000156459021050376/0001564590-21-050376-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636651/000156459021050376/ovid-8k_20211006.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-050376
- JSON: https://secwatch.observer/filing/0001564590-21-050376.json
- Plain text: https://secwatch.observer/filing/0001564590-21-050376.txt

## Key facts
- Executive change
  Dr. Kevin Fitzgerald was appointed as director at Ovid Therapeutics Inc..
  - Action: appointed
  - Role: director
  source text: On October 6, 2021, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Ovid Therapeutics Inc. (the “Company”), the Board appointed Dr. Kevin Fitzgerald, Ph.D. as a director of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636651/000156459021050376/0001564590-21-050376-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.